Effective Date: 03-03-2014



NHS MEDICAL POLICY

Bevacizumab Intravitreal Administration Medicine 2014-001

Bevacizumab is a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF). It is designed to bind to and inhibit VEGF.

Intravitreal administration of bevacizumab may be indicated when 1 of the following is

| 1 | Retinopathy of prematurity |
|---|---|
| 2 | Neovascular (wet) age related macular degeneration (AMD) |
| 3 | Proliferative diabetic retinopathy with vitreous hemorrhage |
| 4 | Proliferative diabetic retinopathy as an adjunctive treatment to vitrectomy or photocoagulation. |
| 5 | Diabetic macular edema |
| 6 | Macular edema following central or branch retinal vein occlusion (RVO) |
| 7 | Neovascular glaucoma |
| 8 | Pseudoxanthoma elasticum |
| 9 | Rare causes of choroidal neovascularization (angioid streaks, choroiditis [including choroiditis secondary to ocular histoplasmosis], idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, and trauma) |

- 1. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18:502.
- 2. Arevalo, JF, Wu, L, Sanchez, JG, et al. Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009; 23:117.
- 3. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26:352.
- 4. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113:1695.e1.
- 5. Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye (Lond) 2006; 20:1474.
- 6. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26:699.
- 7. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860.
- 8. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064.
- 9. Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 2006; 124:1365.
- 10. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006; 34:802.
- 11. Ishikawa, K, Honda, S, Tsukahara, Y, Negi, A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009; 23:108.Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26:1006.
- 12. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142:685.
- 13. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117:1078.
- 14. Minnella AM, Savastano CM, Ziccardi L, et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008; 86:683.
- 15. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18:263.
- 16. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92:76.
- 17. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130:972.
- 18. Salam A, DaCosta J, Sivaprasad S. Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol 2010; 94:821.

- 19. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145:854.
- 20. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011; :CD008214.
- 21. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116:1142.
- 22. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26:275.
- 23. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2012; 12:CD007419.
- 24. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95:1216.

CODE REFERENCE (This may not be a comprehensive list of codes to apply to this policy.)

CPT 67028 HCPCS J9035

POLICY HISTORY/REVISION INFORMATION

| Date | Action/Description |
|------------|---|
| 11/24/2014 | Updated code reference. |
| 03/20/2015 | Annual review and approval by UM Committee |
| 12/16/15 | Annual review and approval by UM Committee |
| 12/14/2016 | Annual review and approval by UM Committee |
| 12/13/2017 | Annual review and approval by UM Committee |
| 12/13/2018 | Annual review and approval by UM Committee |
| 12/12/2019 | Annual review and approval by UM Committee |
| 12/10/2020 | Annual review and approval by UM Committee |
| 12/10/2021 | Annual review and approval by UM Committee |
| 12/21/2022 | Annual review and approval by UM Committee |
| 12/20/2023 | Annual review and approval by UM/QM Committee |
| 12/23/2024 | Annual review and approval by UM/QM Committee |
| 09/30/2025 | Annual review and approval by UM/QM Committee |